跳至主要内容
临床试验/ACTRN12610000882022
ACTRN12610000882022已完成未知

Efficacy and safety of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated falciparum malaria, and chloroquine for P.vivax in Budethaung (Rakhine), Thanphyuzayat (Mon State), and Kawthaung (Tanintharyi Division)

Department of Medical Research (Lower Myanmar)0 个研究点目标入组 160 人开始时间: 2010年10月19日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
160

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Non-randomised trial
主要目的
Treatment
盲法
Open (masking not used)

入排标准

年龄范围
6 Years 至 60 Years(—)
性别
All

入选标准

  • *age between 6 years inclusive and above except females aged 12-17 year old inclusive;
  • *mono-infection with P. falciparum detected by microscopy (parasitaemia of 500-100,000/microliter asexual forms);
  • *presence of axillary equal to or more than 37.5 degrees centigrade or history of fever during the past 24 hours;
  • *ability to swallow oral medication;
  • *ability and willingness to comply with the study protocol for the duration of the study and to comply with the study visit schedule; and
  • *informed consent from the patient or from a parent or guardian in the case of children.

排除标准

  • *presence of signs of severe falciparum malaria according to the definitions of World Health Organisation (WHO);
  • *mixed or mono-infection with another Plasmodium species detected by microscopy;
  • *presence of severe malnutrition (defined as a child whose growth standard is below 3 z-score, has symmetrical oedema involving at least the feet or has a mid-upper arm circumference below 110 mm);
  • *presence of febrile conditions due to diseases other than malaria (e.g. measles, acute lower respiratory tract infection, severe diarrhoea with dehydration) or other known underlying chronic or severe diseases (e.g. cardiac, renal and hepatic diseases, Human Immune Deficiency Virus (HIV)/Acquired Immune Deficiency Syndrom (AIDS);
  • *regular medication, which may interfere with antimalarial pharmacokinetics;
  • *history of hypersensitivity reactions or contraindications to any of the medicine(s) being tested or used as alternative treatment(s); and
  • *a positive pregnancy test or breastfeeding;
  • *unable to or unwilling to take a pregnancy test or contraceptives.

研究者

发起方
Department of Medical Research (Lower Myanmar)

相似试验

已完成
4 期
Efficacy and safety of artemether-lumefantrine and artesunate-amodiaquine for the treatment of uncomplicated Plasmodium falciparum in Dolisie, Republic of CongoInfection - Studies of infection and infectious agentsMalaria
ACTRN12616001422415Ministry of Health and Population176
尚未招募
4 期
Efficacy and safety of artemether-lumefantrine and artesunate-amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Ouesso,Malaria
PACTR201905606150545Health Ministry of Congo176
已完成
不适用
Efficacy and safety of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria, and chloroquine for P.vivax in Kyaing Tone (Eastern Shan State)Infection - Other infectious diseasesmalaria
ACTRN12610000881033Clinical Research Unit (Malaria), Ministry of Defense160
尚未招募
4 期
Efficacy and safety of artemether-lumefantrine and artesunate-mefloquine for the treatment of uncomplicated falciparum malaria, and chloroquine for vivax malaria in Mu-se Township, Northern Shan State and Kalay-Ta-mu townships, Sagaing Region, MyanmarInfection - Studies of infection and infectious agentsMalaria
ACTRN12611001245987Department of Medical Research (Upper Myanmar)480
已完成
不适用
Efficacy and safety of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria, and chloroquine for P.vivax in Myit Kyi Nar Township, Kachin State, Myanmarmalaria
ACTRN12610000880044Department of Medical Research (Upper Myanmar), Ministry of Health240